Reply to: “STRIDE's efficacy and safety in Asian hepatocellular carcinoma” Correspondence

  

Authors:	Lau, G.; Abou-Alfa, G. K.; Chan, S. L.
Title:	Reply to: “STRIDE's efficacy and safety in Asian hepatocellular carcinoma”
Keywords:	cancer survival; controlled study; overall survival; drug efficacy; drug safety; liver cell carcinoma; nonhuman; side effect; unspecified side effect; letter; ticilimumab; safety; drug therapy; hepatitis b virus; adverse drug reaction; therapy; asian; human; durvalumab; checkpoint inhibitor therapy
Journal Title:	Journal of Hepatology
Volume:	82
Issue:	6
ISSN:	0168-8278
Publisher:	Elsevier Science, Inc.
Date Published:	2025-06-01
Start Page:	e346
End Page:	e347
Language:	English
DOI:	10.1016/j.jhep.2025.02.037
PUBMED:	40024547
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105002674869&doi=10.1016%2fj.jhep.2025.02.037&partnerID=40&md5=63c97d973d9707c54020f38ba708af4c
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225663